Rather than do away with RTCs, do them more efficiently. A core team of five people just used crowdsourcing and telemonitoring to design a Phase 2a drug study for $1.4 million: 180 patients, 12 months, biometric telemonitoring, ePROs, virtual study visits with 2-way video, medication adherence monitoring and activity monitoring. Patients will go to a study site at enrollment and completion only-- all other data collected in the home. Less burden on patients = easier recruitment & better retention. FDA is open to this-- the industry is dragging its heels.